SKA 31

Pricing Availability   Qty
Cat.No. 3670 - SKA 31 | C11H8N2S | CAS No. 40172-65-4
说明: KCa3.1 (IK) and KCa2 (SK) channel activator
化学名: Naphtho[1,2-d]thiazol-2-ylamine
纯度: ≥99% (HPLC)
说明书
引用文献
评论 (1)
文献 (2)

生物活性 for SKA 31

SKA 31 is an activator of KCa3.1 and KCa2 channels (EC50 values are 260, 2900, 2900 nM for KCa3.1, KCa2.1 and KCa2.2 respectively). Potentiates acetylcholine-induced EDHF-type dilations of mouse carotid arteries and lowers blood pressure in normotensive and hypertensive mice.

化合物库 for SKA 31

SKA 31 is also offered as part of the Tocriscreen 2.0 Max. 了解 Tocris 化合物库的更多信息。

技术数据 for SKA 31

分子量 200.26
公式 C11H8N2S
储存 Store at +4°C
纯度 ≥99% (HPLC)
CAS Number 40172-65-4
PubChem ID 94880
InChI Key FECQXVPRUCCUIL-UHFFFAOYSA-N
Smiles NC3=NC2=C(S3)C=CC1=CC=CC=C12

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for SKA 31

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
DMSO 20.03 100
ethanol 20.03 100

制备储备液 for SKA 31

以下数据基于产品分子量 200.26。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
1 mM 4.99 mL 24.97 mL 49.94 mL
5 mM 1 mL 4.99 mL 9.99 mL
10 mM 0.5 mL 2.5 mL 4.99 mL
50 mM 0.1 mL 0.5 mL 1 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

参考文献 for SKA 31

参考文献是支持产品生物活性的出版物。

Sankaranarayanan et al (2009) Naphtho[1,2-d]thaizol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol.Pharmacol. 75 281 PMID: 18955585

Brahler et al (2009) Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation 119 2323 PMID: 19380617


If you know of a relevant reference for SKA 31, please let us know.

关键词: SKA 31, SKA 31 supplier, Activators, KCa3.1, KCa2.1, KCa2.2, Ca2+-activated, potassium, K+, channels, SK1, SK2, small, conductance, SKA31, Ca2+-Activated, Potassium, Channels, 3670, Tocris Bioscience

篇 SKA 31 的引用文献

引用文献是使用了 Tocris 产品的出版物。

目前没有 SKA 31 的引用文献。 您是否知道使用了 Tocris SKA 31 的优秀论文? 请告知我们.

SKA 31 的评论

平均评分: 5 (Based on 1 Review.)

5 星
100%
4 星
0%
3 星
0%
2 星
0%
1 星
0%

Have you used SKA 31?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Filter by:


SKA 31 is a great channel activator and works well on biological lab conditions.
By Anonymous on 10/13/2018
分析类型: In Vitro
种属: Human

Great product for studies on Kca channel opening as a measure to compare between other activators. Would use again and suggest to others.

review image

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Ion Channel Product Listing

Ion Channel Product Listing

A collection of around 500 products for ion channel research, the listing includes research tools for the study of:

  • Ligand-gated ion channels
  • Voltage-gated ion channels
  • Other Ion Channels
Epilepsy Poster

Epilepsy Poster

Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.